BioCardia, Inc. – NASDAQ:BCDAW

Financial Health
0
1
2
3
4
5
6
7
8
9

BioCardia stock price monthly change

-58.33%
month

BioCardia stock price quarterly change

-50.00%
quarter

BioCardia stock price yearly change

-98.85%
year

BioCardia key metrics

Market Cap
 10.11K
Enterprise value
 12.52B
P/E
 -0.22
EV/Sales
 5247.88
EV/EBITDA
 -710.84
Price/Sales
 5250.28
Price/Book
 2560.74
PEG ratio
 4124678.47
EPS
 -0.46
Revenue
 468K
EBITDA
 -10.15M
Income
 -10.33M
Revenue Q/Q
 -14.06%
Revenue Y/Y
 -65.48%
Profit margin
 -743.04%
Oper. margin
 -244.05%
Gross margin
 0%
EBIT margin
 -244.05%
EBITDA margin
 -2169.44%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

BioCardia stock price history

BioCardia stock forecast

BioCardia financial statements

Profit Margin

BioCardia, Inc. (NASDAQ:BCDAW): Profit margin
Jun 2023 43K -3.42M -7962.79%
Sep 2023 357K -2.57M -721.01%
Dec 2023 13K -2.07M -15938.46%
Mar 2024 55K -2.26M -4121.82%
BCDAW income statement history

Debt to Assets

BioCardia, Inc. (NASDAQ:BCDAW): Debt to assets
Jun 2023 6389000 4.75M 74.41%
Sep 2023 3747000 4.40M 117.61%
Dec 2023 2987000 4.59M 153.67%
Mar 2024 2679000 4.95M 184.92%
BCDAW balance sheet history

Cash Flow

BioCardia, Inc. (NASDAQ:BCDAW): Cash Flow
Jun 2023 -3.15M -2K 2.60M
Sep 2023 -2.41M 0 -58K
Dec 2023 -1.85M 0 1.11M
Mar 2024 -1.53M 0 1.37M
BCDAW cash flow history

BioCardia alternative data

BioCardia
Employees

BioCardia, Inc. (NASDAQ:BCDAW): Employee count
Jan 2024 30
Feb 2024 30
Mar 2024 30
Apr 2024 30
May 2024 16
Jun 2024 16
Jul 2024 16

BioCardia other data

BioCardia
Hedge Funds Holdings Q1 2023

0.02% -0.01%
of BCDAW is owned by hedge funds
4 -1
hedge funds hold BCDAW stock
51.66K -21.6K
shares is hold by hedge funds
BCDAW hedge funds holdings changes

BioCardia
Insider Trading

BioCardia, Inc. (NASDAQ:BCDAW): Insider trades (number of shares)
Period Buy Sel
Apr 2022 18500 0
May 2022 15000 0
Jun 2022 4500 0
Sep 2022 7250 0
Oct 2022 2000 0
Nov 2022 4500 0
Dec 2022 595238 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
FROST PHILLIP MD ET AL 10 percent owner Common Stock 595,238 $1.68 $1,000,000
Purchase
FROST PHILLIP MD ET AL 10 percent owner Common Stock 595,238 $1.68 $1,000,000
Purchase
ALTMAN PETER director, officer.. Common Stock 1,400 $1.86 $2,604
Purchase
ALTMAN PETER director, officer.. Common Stock 3,100 $1.87 $5,797
Purchase
MCCLUNG DAVID officer: Chief Fi.. Common Stock 2,000 $2.07 $4,140
Purchase
ALTMAN PETER director, officer.. Common Stock 1,400 $1.87 $2,618
Purchase
ALTMAN PETER director, officer.. Common Stock 3,100 $1.81 $5,611
Purchase
ALTMAN PETER director, officer.. Common Stock 2,750 $1.92 $5,280
Purchase
ALTMAN PETER director, officer.. Common Stock 4,500 $1.46 $6,570
Purchase
ALTMAN PETER director, officer.. Common Stock 2,698 $1.38 $3,723
BCDAW insider trading transactions

Frequently Asked Questions (FAQ)

  • When is BioCardia's next earnings date?

    Unfortunately, BioCardia's (BCDAW) next earnings date is currently unknown.

  • Does BioCardia pay dividends?

    No, BioCardia does not pay dividends.

  • How much money does BioCardia make?

    BioCardia has a market capitalization of 10.11K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 64.72% to 477K US dollars.

  • What is BioCardia's stock symbol?

    BioCardia, Inc. is traded on the NASDAQ under the ticker symbol "BCDAW".

  • What is BioCardia's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of BioCardia?

    Shares of BioCardia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does BioCardia have?

    As Jul 2024, BioCardia employs 16 workers, which is 47% less then previous quarter.

  • When BioCardia went public?

    BioCardia, Inc. is publicly traded company for more then 6 years since IPO on 2 Aug 2019.

  • What is BioCardia's official website?

    The official website for BioCardia is biocardia.com.

  • How can i contact BioCardia?

    BioCardia can be reached via phone at +65 02260120.

BioCardia company profile:

BioCardia, Inc.

biocardia.com
Exchange:

NASDAQ

Full time employees:

16

Industry:

Biotechnology

Sector:

Healthcare

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

+65 02260120
320 Soquel Way
Sunnyvale, 94085

CIK: 0000925741
ISIN: US09060U1198
CUSIP: 09060U119